SCHEMBL14076165

SCHEMBL14076165

CNCc1ccnc(CO)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 4/20 0.42
▸ RECQL P46063 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ ADRB2 P07550 1/20 0.39
▸ NOS1 P29475 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TYMS P04818 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ CSNK1D P48730 1/20 0.35
▸ CSNK1E P49674 1/20 0.35
▸ PDCD1 Q15116 1/20 0.35
▸ CD274 Q9NZQ7 1/20 0.35
▸ GRM2 Q14416 1/20 0.34
▸ LOXL2 Q9Y4K0 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TAAR1 Q96RJ0 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23891936 0.82 CYP1A2 (0.44) PRMT6EPHX2ADRB2NOS1KDM4E
SCHEMBL18880283 0.81 PRMT6 (0.42) PRMT6EPHX2ADRB2NOS1KDM4E
SCHEMBL13541414 0.79 RECQL (0.61) RECQLNOS1TYMSCSNK1DCSNK1E
SCHEMBL10154332 0.78 PRMT6 (0.43) PRMT6RECQLEPHX2ADRB2NOS1
SCHEMBL12213655 0.78 PRMT6 (0.46) PRMT6EPHX2ADRB2NOS1KDM4E
SCHEMBL5115940 0.78 NOS3 (0.55) RECQLNOS1KDM4ECYP3A4TYMS
SCHEMBL8485243 0.76 UHRF1 (0.46) PRMT6EPHX2ADRB2KDM4ECYP3A4
SCHEMBL14076711 0.74 PRMT6 (0.43) PRMT6EPHX2ADRB2NOS1KDM4E
SCHEMBL12536053 0.74 LOXL2 (0.57) PRMT6EPHX2ADRB2NOS1KDM4E
SCHEMBL21527214 0.74 NOS3 (0.52) PRMT6ADRB2NOS1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 — — US disclosed
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 — — US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 — — US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE KCNT1, KCNMA1, KCNJ2 PRMT6 2653/4885RECQL 2226/4885EPHX2 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback